Last reviewed · How we verify

NCT07112261

Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study

Active, enrolled NA Last updated 8 August 2025
What this trial tests

NA trial testing Avatar Therapy in Treatment-Resistant Major Depressive Disorder in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 August 2024
Primary endpoint
1 September 2026
1 September 2026

Quick facts

Lead sponsorCiusss de L'Est de l'Île de Montréal
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date1 August 2024
Primary completion1 September 2026
Estimated completion1 September 2026
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Ciusss de L'Est de l'Île de Montréal — full company profile →

Who can join

18 and older, any sex, with Treatment-Resistant Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot clinical trial aimed to evaluate the short-term efficacy of Avatar therapy for treatment-resistant major depressive disorder

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Avatar Therapy

Trials testing the same drug.

Other recruiting trials for Treatment-Resistant Major Depressive Disorder

Currently open trials in the same condition.

Other Ciusss de L'Est de l'Île de Montréal trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07112261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing